


RealRate

PHARMACEUTICAL 2021

PROCYON

PROCYON CORP Rank 22 of 409





PHARMACEUTICAL 2021

RealRate

PROCYON CORP Rank 22 of 409

PROCYON

The relative strengths and weaknesses of PROCYON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROCYON CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 883% points. The greatest weakness of PROCYON CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 282% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 518% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,074
Cost of Goods Sold	1,135
Intangible Assets	17
Liabilities, Current	514
Liabilities, Non-Current	144
Other Assets	278
Other Compr. Net Income	0
Other Expenses	1,778
Other Liabilities	0
Other Net Income	7.0
Property and Equipment	453
Research and Development	0
Revenues	4,334
Selling, General and Administrative Expense	1,317

Output Variable	Value in 1000 USD
Assets	2,822
Liabilities	658
Expenses	4,229
Stockholders Equity	2,164
Net Income	112
Comprehensive Net Income	112
Economic Capital Ratio	163%